Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.
Hiddo Heerspink, PhD, PharmD, was emphatic that general pracitioners can significantly improve the renal health of their patients with type 2 diabetes by following guideline recommendations to measure eGFR and UAC annually.
Here he talks with Patient Care about preliminary findings on the potential role for the novel dual incretin agent tirzepatide in slowing the progression of renal disease, or even stopping it and preventing advanced disease and dialysis.
Hiddo Lambers Heerspink, PhD, PharmD, is professor of clincal trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in Groningen, Netherlands; he is also Codirector of the Better Treatments Program at the George Institute for Global Health in Newtown, Australia.
